Valneva to Participate at U.S. and European Investor Conferences in June 2026

Lyon (France), May 28, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences in the United States and Europe in June 2026.

Key topics for discussion include Valneva’s commercial stage vaccines and its differentiated portfolio of vaccine candidates, including LB6V (formerly VLA15), the world’s leading Lyme Disease vaccine candidate. LB6V is partnered with Pfizer, who reported topline Phase 3 results demonstrating strong efficacy with no safety concerns. Pfizer is currently planning submissions to regulatory authorities.

Institutional investors who would like to meet 1on1 with management at any of the conferences below are asked to submit a request to their representative at the respective bank.

Jefferies Global Healthcare Conference

Format: Fireside chat and investor meetings Date/ time: June 3, 11:40am ET Webcast: Link. A replay will be available in the “Investor” section of the Valneva website. Location: New York

Oddo BHF Nextcap Forum:

Format: Investor meetings only Date/ time: June 12 Location Virtual

BNP Paribas SMID Cap Conference:

Format: Investor meetings only Date/ time: June 24 Location: Paris, France

Additionally, the Company will also engage with travel medical professionals during a key European medical conference, where Valneva is a Gold Sponsor and Exhibitor.

10th Northern European Conference on Travel Medicine (NECTM10)

Date/ time: June 3 - 5 Location: Belfast, Ireland Booth #: 4 Symposium: From Risk to Protection: Real‐World Perspectives on Mosquito‐Borne Diseases; Promotional session; June 5, 12:30pm BST

About Valneva SE

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines. Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at www.valneva.com.

Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP, Global Communications and European Investor Relations M +33 (0)6 4516 7099 [email protected]

Joshua Drumm, Ph.D. VP, Global Investor Relations M +001 917 815 4520 [email protected]